Subscribe
dentist_istock-532326710_pyotr021
pyotr021 / iStockphoto.com
22 February 2018Big Pharma

J&J to boost medical device division with acquisition

Johnson & Johnson (J&J) has revealed plans to strengthen its medical device capabilities with the acquisition of French medical technology company Orthotaxy.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.

More on this story

Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J plans to sell LifeScan for $2.1bn
21 March 2018   Johnson & Johnson has revealed plans to sell LifeScan, its blood glucose monitoring unit, for $2.1 billion.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB